…Canakinumab, a monoclonal antibody directed against interleukin 1β, provided proof of concept but was not developed for routine coronary prevention because of fatal infections…

…thereby enhances removal of LDL C from the circulation. This mechanism differs from that of the monoclonal antibodies alirocumab and evolocumab, which bind circulating PCSK9…

…plasma. Two principal therapeutic strategies have emerged: Inhibition of circulating PCSK9 activity , using the monoclonal antibodies evolocumab and alirocumab. Inhibition of hepatic PCSK9 synthesis , using…